EBMT 2024 | Targeted therapies in AML: menin, FLT3 and IDH inhibitors
Felicitas Thol, MD, Hannover Medical School, Hannover, Germany, discusses advancements in targeted therapies for acute myeloid leukemia (AML). Early trial results show promise for menin inhibitors in NPM1-mutated AML. Additionally, FLT3 inhibitors like gilteritinib and IDH1/2 inhibitors such as ivosidenib and enasidenib demonstrate efficacy. Dr Thol also touches on developments in immunotherapies like CAR T-cells and bispecific antibodies, noting the challenges in AML due to the absence of a distinct target. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
